Check for updates

OPEN ACCESS

EDITED BY Tao Liu, Jinan University, China

REVIEWED BY Qi Zhao, Shandong University, China Jian Song, Anhui Medical University, China

*CORRESPONDENCE Guowei Zhao ⊠ guoweijessen@163.com

RECEIVED 28 April 2024 ACCEPTED 25 November 2024 PUBLISHED 09 December 2024

CITATION

Li Y, Wang H, Bi X and Zhao G (2024) Associations between ethylene oxide exposure and chronic bronchitis: results from the NHANES 2013–2018. *Front. Public Health* 12:1424555. doi: 10.3389/fpubh.2024.1424555

COPYRIGHT

© 2024 Li, Wang, Bi and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Associations between ethylene oxide exposure and chronic bronchitis: results from the NHANES 2013–2018

Yan Li, Hui Wang, Xiaoqing Bi and Guowei Zhao*

Department of Dermatology, ZiBo Central Hospital, Zibo, Shangdong, China

Introduction: Ethylene oxide (EtO) is a reactive gas commonly used in the production of various chemical compounds. Research has linked EtO exposure to respiratory conditions, including chronic obstructive pulmonary disease (COPD) and asthma. However, its potential effects on chronic bronchitis (CB) remain unclear, highlighting the need for further study to understand its role in respiratory health.

Methods: Our study investigated data from 5,044 NHANES participants between 2013 and 2018 across three 2-year survey cycles. The relationship between HbEtO and CB was examined using weighted logistic regression, with HbEtO quartiles analyzed to assess the trend. A smoothed curve was fitted to verify the relationship between HbEtO and CB. Additionally, sensitivity analyses were conducted to assess the robustness of our results, while subgroup analyses explored potential effect modifiers of the HbEtO-CB association.

Results: Compared with patients without CB, patients with CB had elevated HbEtO levels. Specifically, natural Log₂HbEtO levels were linked to a greater prevalence of CB in a fully adjusted model (OR = 1.243, 95% CI: 1.143-1.352). Analysis of Log₂HbEtO quartiles showed a significant trend in Q4 compared with Q1 (*p* for trend < 0.001). The fitted smoothed curve indicated a U-shaped nonlinear association, with saturation and threshold analysis revealing an inflection point at Log₂HbEtO = 4.87. Sensitivity analyses confirmed the robustness of these findings, and subgroup analyses identified consistent associations across various groups.

Conclusion: Our study found a significant association between EtO exposure and the occurrence of CB. Given the health risks linked to EtO exposure, implementing effective control measures is essential. Such actions could help lower CB prevalence and enhance respiratory health in vulnerable populations.

KEYWORDS

ethylene oxide, chronic bronchitis, NHANES, cross-sectional study, epidemiology

1 Introduction

Ethylene oxide (EtO) is a reactive epoxide that is an important raw material for the production of ethoxylates and other compounds used in a wide variety of industrial processes (1). It is present in everyday products such as disinfectants for medical equipment, fumigants and chemicals used in the production of cosmetics, detergents and pharmaceuticals (2). Ethylene oxide is one of the most produced organic compounds, with a global production of more than 20 million tons. Due to its wide industrial application, people are exposed to ethylene oxide not only in occupational settings (3, 4), but also

through environmental contamination (e.g., air pollution and contaminated food or water). In the human body, ethylene oxide is rapidly absorbed by inhalation and distributed throughout the body, forming adducts with hemoglobin (5, 6) and DNA (7, 8). Although adverse health effects of ethylene oxide have been extensively documented in animal models (2, 9, 10), the effects on human health, particularly on non-cancer outcomes such as chronic bronchitis (CB), remain under-explored. Prolonged exposure to ethylene oxide for industrial workers or those living near ethylene oxide-emitting facilities may lead to long-term health consequences (11–14).

CB is a common respiratory disease affecting 12 to 16 million individuals in the United States (15), where it has consistently been the third leading cause of death since 2008 (16, 17). CB is marked by persistent coughing and mucus production that typically last about 2 years, with symptoms recurring for at least 3 months each year. This condition can accelerate lung function decline, increase rates of exacerbation, and potentially raise overall mortality. CB is an important public health problem affecting millions of people worldwide. CB is characterized by persistent cough and sputum, usually due to prolonged exposure to irritants. Although smoking is the main risk factor, environmental pollutants such as ethylene oxide may also contribute to the pathogenesis of CB (18, 19). However, further direct studies are needed to more fully understand the mechanisms by which ethylene oxide affects human health.

The median prevalence of CB in Europe is 2.6%. While smoking accounts for only 30% of this prevalence, other factors, such as EtO exposure, may also play a significant role (20). In 2016, the U.S. Environmental Protection Agency (USEPA) reevaluated the toxicity of EtO, more than doubling the unit risk level from previous estimates. This has raised public awareness and concerns over the health risks associated with EtO exposure. Prolonged exposure to EtO is linked to cancer and neurological disorders, and it can also lead to symptoms like nausea, pulmonary edema, and bronchitis (21, 22). Despite these recognized effects, the relationship between EtO exposure and bronchitis remains underexplored. Given the respiratory risks associated with frequent EtO exposure, understanding its health impact is essential. This study, therefore, utilized data from a U.S. population sample to examine the potential link between EtO exposure and CB.

2 Methods

2.1 Study population

This study utilized data from the National Health and Nutrition Examination Survey (NHANES), a program designed to assess various aspects of health and nutrition in the U.S. population. To accurately reflect the population's overall health, NHANES employed a stratified, multistage probability sampling method (23). Data for this analysis were sourced from the NHANES public database, available at https://wwwn.cdc.gov/nchs/nhanes (24).

The analysis included data from 29,400 individuals surveyed between 2013 and 2018. Of these, 40 individuals who reported being pregnant, 12,372 with no data on CB, and 11,944 without hemoglobin adduct of ethylene oxide (HbEtO) data were excluded. After these exclusions, the final sample consisted of 5,044 individuals, including 307 with CB and 4,737 without (Figure 1).

2.2 The definition of CB

CB was identified based on participants' self-reported medical history collected through a standardized questionnaire. During the survey, participants were asked, "Have you ever been told by a doctor or other healthcare professional that you have CB?" Those who responded "yes" were classified as having CB, ensuring that only cases diagnosed by qualified healthcare providers were included (25).

2.3 Measurement of HbEtO hemoglobin adducts

HbEtO is a reliable marker for cumulative EtO exposure due to its extended biological half-life of up to 4 months. This prolonged half-life allows HbEtO levels to reflect sustained exposure, making it suitable for assessing chronic exposure risks. In this study, HbEtO levels were measured to estimate participants' internal EtO dose. EtO hemoglobin adducts in red blood cells were quantified using a modified Edman reaction, following the protocols in the NHANES Laboratory Procedures Manual. Samples were preserved at -30° C to maintain accuracy, with any data irregularities reviewed rigorously by contract laboratories. Whole-blood hemoglobin content was measured through liquid chromatography-tandem mass spectrometry, while HbEtO was quantified using highperformance liquid chromatography (HPLC), with results reported in pmol/g Hb. This approach provides a dependable measure of EtO exposure through HbEtO levels (26, 27).

2.4 Covariates

Data were gathered through questionnaires, laboratory tests, and physical examinations, with covariate selection validated using a Directed Acyclic Graph (DAG) in Supplementary Figure 1 to ensure appropriate inclusion and minimize confounding. Key covariates included sex (female/male), age, and race (Mexican American, Other Hispanic, Non-Hispanic Black, Other Race). Education level was classified as less than high school, high school or equivalent, and college or higher. Poverty-to-income ratios (PIRs) were grouped into <1.3, 1.3–3.5, and >3.5. Smoking status was defined as a lifetime consumption of over 100 cigarettes, and body mass index (BMI) was categorized into <25, 25–30, and >30 kg/m². Sedentary activity was classified based on self-reported duration as <3 h, 3-6 h, or >6 h per day. Alcohol consumption was

Abbreviations: HbEtO, Hemoglobin adducts of ethylene oxide; Log₂HbEtO, Natural Log₂-transformed hemoglobin adducts of ethylene oxide; EtO, Ethylene oxide; BMI, Body mass index; CB, Chronic bronchitis; PIRs, Poverty-to-income ratios; CI, Confidence interval; NHANES, National Health and Nutrition Examination Survey; OR, Odds ratio; CDC, Centers for Disease Control and Prevention.



defined as four or more drinks within a 2-h period per day. Self-reported diagnoses of diabetes and hypertension were also included in the analysis (28–30).

2.5 Statistical analysis

NHANES sampling weights were applied following CDC guidelines to ensure accurate statistical analysis. Baseline characteristics were presented as means \pm standard deviations for continuous variables, analyzed using weighted t-tests, and as proportions for categorical variables, assessed using chi-square tests. Missing data were managed through multiple imputation to enhance the robustness of the analysis. To examine the association between HbEtO levels and CB, we used logistic regression models with weighted variables. HbEtO levels were categorized into quartiles for trend analysis. Model 1 included no covariates, Model 2 adjusted for demographic variables, and Model 3 further controlled for alcohol consumption, education level, smoking status, BMI, PIR, diabetes, hypertension, and sedentary time. Due to the skewness in HbEtO data, we applied a logarithmic transformation (Log₂HbEtO) to approximate a normal distribution (31). A weighted smoothing curve was fitted to assess any nonlinear relationship between Log₂HbEtO and CB, with a threshold effect analysis to identify potential inflection points. Additionally, a subgroup analysis was conducted to explore potential effect modifiers in the Log₂HbEtO-CB association (32). All statistical analyses were performed using R version 4.2.0 and Empower software (X&Y Solutions). A p < 0.05 was considered statistically significant (33).

3 Results

3.1 Baseline characteristics

Table 1 summarizes the baseline characteristics of the 5,044 participants. The sample is nearly evenly split by sex, with 50.2% female and 49.8% male, and has an average age of 48.2 years (\pm 16.9). Non-Hispanic whites make up the majority (64.3%), and 6.1% of participants (307 individuals) reported CB. Key demographic differences are observed between those with and without CB: participants with CB are generally older, averaging 55.2 years compared to 47.7 years in those without CB, and include a higher proportion of females (64.4%) and Non-Hispanic whites (75.5%).

Socioeconomic and health factors also differ between groups. Participants with CB tend to have lower education levels and lower PIRs, with 28.2% having a ratio below 1.3. They report higher rates of smoking (69.4%) and more frequent alcohol consumption, with 20.3% consuming four or more drinks per day. Health indicators reveal increased rates of diabetes (19.3%) and hypertension (46.2%) in the CB group, along with a higher prevalence of obesity (50.9% with a BMI above 30 kg/m²). Additionally, Log₂HbEtO levels are significantly higher in the CB group (5.3 \pm 1.8 pmol/g Hb) than in those without CB (4.8 \pm 1.5 pmol/g Hb), suggesting a potential link between ethylene oxide exposure and CB risk.

3.2 The association between Log₂HbEtO and CB

Table 2 demonstrates a strong association between Log₂HbEtO levels and CB risk. In both Models 1 and 2, elevated Log₂HbEtO levels were consistently linked to an increased risk of CB (Model 1: OR = 1.329, 95% CI: 1.243–1.420; Model 2: OR = 1.375, 95% CI: 1.282–1.474). After adjusting for all covariates in Model 3, each unit increase in Log₂HbEtO was associated with a 24.3% greater likelihood of CB (OR = 1.243, 95% CI: 1.143–1.352). This association remained significant when Log₂HbEtO levels were analyzed in quartiles. Across all models, participants in the highest quartile (Q4) had a markedly higher risk of CB than those in the lowest quartile (Q1) (P < 0.001). In Model 3, individuals in Q4 had more than twice the odds of CB compared to those in Q1 (OR = 2.096; 95% CI = 1.446–3.039, P < 0.001).

3.3 Association between Log₂HbEtO and CB in subgroups

Subgroup analyses explored the association between Log₂HbEtO levels and CB across various demographic and socioeconomic groups, as shown in Table 3. The positive association between elevated Log₂HbEtO levels and CB was statistically significant in most subgroups. However, certain groups, including individuals with a poverty-to-income ratio (PIR) above 3.5, Mexican Americans, Non-Hispanic Blacks, Other Hispanics, and those from other racial backgrounds, did not show significant associations (P > 0.05). These findings suggest that socioeconomic and racial factors may influence the relationship between Log₂HbEtO and CB, potentially due to varying levels or sources of exposure. Moreover, none of the covariates significantly modified the Log₂HbEtO-CB relationship, as indicated by interaction terms with P-values exceeding 0.05 for all variables. This lack of significant interaction suggests that while there are overall trends, no specific covariate substantially alters the effect of Log₂HbEtO on CB across these subgroups.

3.4 Sensitivity analysis of key determinants in CB risk

Using logistic regression with robust standard errors, the analysis in Supplementary Table 2 reveals a significant association between Log_2HbEtO levels and the risk of CB. Higher Log_2HbEtO levels were linked to an increased likelihood of CB (coefficient =

0.202, P < 0.001). This method was chosen to improve the precision of the findings by controlling for data variability and minimizing the influence of outliers.

This association was further influenced by individual characteristics. Males and older adults showed a higher risk of CB (gender coefficient = 0.601, P = 0.001; age coefficient = 0.026, P < 0.001). Additionally, body mass index (BMI) and economic status, represented by the Poverty Index Ratio (PIR), were significant factors. Higher BMI was positively associated with CB risk (BMI coefficient = 0.049, P < 0.001), while a higher PIR, reflecting better economic status, was associated with a reduced likelihood of CB (PIR coefficient = -0.204, P = 0.002). Smoking status was also an important factor, with findings underscoring its role in elevating CB risk (smoking coefficient = -0.517, P = 0.014).

3.5 Nonlinear relationship between Log₂HbEtO and CB

The fully adjusted model reveals a smooth curve indicating a significant positive association between Log₂HbEtO levels and CB risk, displaying a U-shaped nonlinear pattern (P < 0.001) (Figure 2). This pattern suggests that CB risk increases at both lower and higher levels of Log₂HbEtO, underscoring the complexity of this relationship. A critical inflection point was identified at a Log₂HbEtO level of 4.87; beyond this threshold, CB risk rises markedly. These findings highlight the importance of monitoring and managing EtO exposure to effectively reduce the risk of CB.

4 Discussion

This cross-sectional survey is the first to examine the relationship between CB prevalence and Log_2HbEtO levels. After accounting for all covariates, a positive association between CB and Log_2HbEtO was identified. The fitted smoothed curves reveal a U-shaped pattern, indicating that both low and high levels of Log_2HbEtO are linked to increased CB risk. Additionally, the analysis of saturation and threshold effects identified an inflection point at a Log_2HbEtO level of 4.87. These findings underscore the potential impact of Log_2HbEtO on CB and highlight the importance of monitoring and mitigating its adverse effects on health.

Previous studies have highlighted the serious health effects of ethylene oxide (EtO) exposure (34). The International Agency for Research on Cancer (IARC) has classified EtO as a Group 1 carcinogen based on data from epidemiological and animal studies (35). Numerous investigations confirm a strong association between EtO exposure and the risk of developing various cancers (34–37). In animal studies, EtO exposure has been linked to significantly lower antioxidant levels, which can lead to the development of malignant tumors in multiple organs (38). Additionally, several cross-sectional studies have connected EtO exposure to health issues such as obesity, diabetes, depression, and hypertension (26, 31, 39, 40). Research has also shown that EtO exposure increases the risk of chronic respiratory diseases (28). In the general U.S. population, greater EtO exposure correlates with a

TABLE 1 Participants with/without chronic bronchitis.

Characteristics	Tota	Without CB	With CB	<i>P</i> -value
	<i>N</i> = 5,044	N = 4,737	<i>N</i> = 307	
Age, years	48.2 ± 16.9	47.7 ± 16.9	55.2 ± 16.0	< 0.001
Gender, %				< 0.001
Female	2,532 (50.2%)	2,331 (49.2%)	198 (64.4%)	
Male	2,512 (49.8%)	2,406 (50.8%)	109 (35.6%)	
Race/ethnicity, %				< 0.001
Mexican American	474 (9.4%)	464 (9.8%)	11 (3.5%)	
Other Hispanic	318 (6.3%)	303 (6.4%)	13 (4.1%)	
Non-Hispanic white	3,243 (64.3%)	3,017 (63.7%)	232 (75.5%)	
Non-Hispanic black	540 (10.7%)	512 (10.8%)	29 (9.3%)	
Other race	469 (9.3%)	445 (9.4%)	24 (7.8%)	
Education level, %				< 0.001
Under high school	691 (13.7%)	649 (13.7%)	42 (13.6%)	
High school or equivalent	1,211 (24.0%)	1,104 (23.3%)	104 (33.8%)	
College graduate or above	3,142 (62.3%)	2,984 (63.0%)	162 (52.7%)	
PIRs, %				< 0.001
< 1.3	1,004 (19.9%)	914 (19.3%)	87 (28.2%)	
1.3-3.5	2,073 (41.1%)	1,933 (40.8%)	142 (46.4%)	
>3.5	1,967 (39.0%)	1,890 (39.9%)	78 (25.4%)	
BMI (kg/m²), %				< 0.001
< 25	1,352 (26.8%)	1,307 (27.6%)	42 (13.8%)	
25-30	1,659 (32.9%)	1,549 (32.7%)	108 (35.3%)	
> 30	2,033 (40.3%)	1,881 (39.7%)	156 (50.9%)	
Smoking status, %				< 0.001
Yes	2,214 (43.9%)	1,999 (42.2%)	213 (69.4%)	
No	2,830 (56.1%)	2,738 (57.8%)	94 (30.6%)	
Alcohol consumption, %				0.001
<4 drinks/day	4,333 (85.9%)	4,088 (86.3%)	245 (79.7%)	
≥4 drinks/day	711 (14.1%)	649 (13.7%)	62 (20.3%)	
Diabetes, %				< 0.001
Yes	540 (10.7%)	478 (10.1%)	59 (19.3%)	
No	4,504 (89.3%)	4,259 (89.9%)	248 (80.7%)	
Hypertension, %				<0.001
Yes	1,654 (32.8%)	1,516 (32.0%)	142 (46.2%)	
No	3,390 (67.2%)	3,221 (68.0%)	165 (53.8%)	
Sedentary time, h, %				0.163
<3h	994 (19.7%)	947 (20.0%)	50 (16.2%)	
3-6 h	1,745 (34.6%)	1,630 (34.4%)	118 (38.5%)	
>6 h	2,305 (45.7%)	2,165 (45.7%)	139 (45.2%)	
Log ₂ HbEtO, pmol/g Hb	4.8 ± 1.5	4.8 ± 1.5	5.3 ± 1.8	<0.001

PIRs, poverty-to-income ratios; BMI, body mass index; Log2HbEtO, Natural Log2-transformed hemoglobin adducts of ethylene oxide; CB, chronic bronchitis.

TABLE 2 Correlation between Log₂HbEtO levels and the presence of CB.

	Model 1		Model 2		Model 3	
Variable	(OR, 95% CI)	P-value	(OR, 95% CI)	P-value	(OR, 95% CI)	P-value
Log ₂ HbEtO (continuous)	1.329 (1.243, 1.420)	< 0.001	1.375 (1.282, 1.474)	< 0.001	1.243 (1.143, 1.352)	< 0.001
Log ₂ HbEtO (quartile)						
Q1 (<3.99)	Reference		Reference		Reference	
Q2 (3.99-4.45)	0.971 (0.669, 1.409)	0.878	1.037 (0.711, 1.512)	0.851	1.035 (0.704, 1.522)	0.860
Q3 (4.45-5.44)	0.905 (0.621, 1.321)	0.606	1.064 (0.724, 1.565)	0.751	1.045 (0.705, 1.549)	0.828
Q4 (>5.44)	2.483 (1.811, 3.405)	< 0.001	3.125 (2.250, 4.339)	< 0.001	2.096 (1.446, 3.039)	< 0.001
P for trend	<0.001		<0.001		<0.001	

Model 1: No covariates were adjusted. Model 2: adjusted for age, sex, race. Model 3: adjusted for age, sex, race, education level, PIRs, BMI, smoking status, alcohol consumption, hypertension, diabetes, and sedentary time.

Log₂HbEtO, Natural Log₂-transformed hemoglobin adducts of ethylene oxide.



higher risk of asthma (27). Studies, such as those by Klonne et al., have reported that long-term inhalation of EtO causes lung fibrosis in F-344 rats, while findings from the U.S. (41). National Toxicology Program indicate a significant association between lung cancer prevalence in B6C3F1 mice and prolonged EtO exposure (42), also noting its link to inflammation (38, 43). Our study also identified an association between EtO exposure and CB, supported by a Ushaped pattern in the smoothed curve, which suggests that EtO exposure increases the risk of CB. The strength of this relationship is further underscored by consistent results in subgroup analyses. However, the lack of statistically significant associations in certain subgroups, such as those with higher poverty-to-income ratios or specific racial and ethnic backgrounds, may indicate differences in exposure sources or levels. For instance, individuals with higher incomes or from certain racial/ethnic groups may experience unique exposure characteristics or occupational risks that influence their susceptibility to EtO. Furthermore, smaller sample sizes within some subgroups could have limited statistical power, leading to non-significant *P*-values even when trends suggest a potential association. These findings emphasize the need to consider population diversity when evaluating the health effects of EtO exposure. Future studies should further explore these subgroup differences to better understand the implications of EtO on CB risk.

The findings of this study highlight the need for further research to fully understand the relationship between ethylene oxide (EtO) exposure and CB. A consistent positive association was observed, indicating that the prevalence of CB may significantly rise with increasing levels of EtO exposure. Notably, a strong correlation between EtO exposure and tobacco exposure was found, suggesting that direct contact with tobacco and its emitted EtO heightens the risk of bronchial diseases (44). The specific mechanisms behind this association warrant additional investigation. EtO exposure may lead to oxidative stress, which depletes cytoplasmic content and results in cell shrinkage, ultimately damaging vital organs and triggering bronchial inflammation. The detrimental effects of this oxidative stress can significantly impact health. Furthermore, research by Lynch et al. demonstrated that EtO exposure causes inflammation in the locomotor organs of rodents, suggesting that the inflammatory response associated with EtO exposure may negatively affect bronchial health (39, 43, 45). However, the precise mechanisms at play still require further exploration.

This study utilized data from approximately 29,400 NHANES participants collected between 2013 and 2018, ultimately analyzing data from 5,044 individuals after excluding those with missing information on HbEtO and CB. As detailed in Supplementary Table 1, individuals lacking HbEtO or CB data were significantly younger than those included in the final analysis, with notable differences in age, sex, and race. The observed age differences among those with missing data may stem from several factors. First, younger individuals are generally less exposed to occupational or environmental HbEtO, which may lead to a lower priority for data collection in this demographic. Second, NHANES data collection relies heavily on self-reported information and follow-up, and health assessments for younger participants may

AgeImage of the set	Characteristics	CB [β (95%CI)]	<i>P-</i> value	P for interaction
> 60 years 1.25 (1.11, 1.41) <0.001	Age			0.568
GenderImageImageImageImageImageImageFemale1.26 (1.14, 1.40)<0.001	\leq 60 years	1.20 (1.08, 1.33)	< 0.001	
Female1.26 (1.14, 1.40)<0.001Male1.17 (1.04, 1.31)0.008Mack1.17 (1.04, 1.31)0.008Race/ethnicity0.79 (0.52, 1.21)0.280Mexican American0.79 (0.52, 1.21)0.280Other Hispanic1.15 (0.79, 1.68)0.459Non-Hispanic White1.26 (1.13, 1.40)<0.001	>60 years	1.25 (1.11, 1.41)	< 0.001	
Male 1.17 (1.04, 1.31) 0.008 Race/ethnicity 0.274 Mexican American 0.79 (0.52, 1.21) 0.280 Other Hispanic 1.15 (0.79, 1.68) 0.459 Non-Hispanic White 1.26 (1.13, 1.40) <0.001	Gender			0.262
Race/ethnicityImage: style st	Female	1.26 (1.14, 1.40)	< 0.001	
Mexican American 0.79 (0.52, 1.21) 0.280 Other Hispanic 1.15 (0.79, 1.68) 0.459 Non-Hispanic White 1.26 (1.13, 1.40) <0.001	Male	1.17 (1.04, 1.31)	0.008	
Other Hispanic 1.15 (0.79, 1.68) 0.459 Non-Hispanic White 1.26 (1.13, 1.40) <0.001	Race/ethnicity			0.274
Non-Hispanic White 1.26 (1.13, 1.40) <0.001 Non-Hispanic Black 1.22 (1.00, 1.49) 0.050 Other race 1.32 (0.98, 1.79) 0.069 PIRs 0.135 <1.3	Mexican American	0.79 (0.52, 1.21)	0.280	
Non-Hispanic Black 1.22 (1.00, 1.49) 0.050 Other race 1.32 (0.98, 1.79) 0.069 PIRs 0.135 <1.3	Other Hispanic	1.15 (0.79, 1.68)	0.459	
Other race 1.32 (0.98, 1.79) 0.069 PIRs 0.135 <1.3	Non-Hispanic White	1.26 (1.13, 1.40)	< 0.001	
PIRs 0.135 < 1.3	Non-Hispanic Black	1.22 (1.00, 1.49)	0.050	
< 1.3	Other race	1.32 (0.98, 1.79)	0.069	
1.3-3.5 1.23 (1.10, 1.39) <0.001 >3.5 1.01 (0.80, 1.26) 0.955 BMI (kg/m²) 0.503 < 25	PIRs			0.135
>3.5 1.01 (0.80, 1.26) 0.955 BMI (kg/m ²) 0.503 < 25	< 1.3	1.31 (1.14, 1.49)	< 0.001	
BMI (kg/m²) 0.503 < 25	1.3-3.5	1.23 (1.10, 1.39)	< 0.001	
< 1.25 (1.05, 1.48) 0.013 25-30 1.29 (1.12, 1.49) <0.001	>3.5	1.01 (0.80, 1.26)	0.955	
$25-30$ $1.29 (1.12, 1.49)$ <0.001 > 30 $1.16 (1.04, 1.30)$ 0.010 Smoking status 0.400 Yes $1.20 (1.10, 1.30)$ <0.001 No $1.33 (1.05, 1.69)$ 0.017 Alcohol consumption 0.778 $<4 drinks/day$ $1.21 (1.10, 1.33)$ <0.001 $\geq 4 drinks/day$ $1.24 (1.07, 1.45)$ 0.006 Diabetes 0.313 0.001 No $1.20 (1.09, 1.32)$ <0.001 No $1.20 (1.09, 1.32)$ <0.001 Hypertension 0.364 Yes $1.26 (1.13, 1.41)$ <0.001 No $1.17 (1.05, 1.31)$ 0.006 Sedentary time, h 0.838 $< 3h$ $1.25 (1.03, 1.52)$ 0.013	BMI (kg/m ²)			0.503
> 30 1.16 (1.04, 1.30) 0.010 Smoking status 0.400 Yes 1.20 (1.10, 1.30) <0.001	< 25	1.25 (1.05, 1.48)	0.013	
Smoking status 0.400 Yes 1.20 (1.10, 1.30) <0.001	25-30	1.29 (1.12, 1.49)	< 0.001	
Yes 1.20 (1.10, 1.30) <0.001 No 1.33 (1.05, 1.69) 0.017 Alcohol consumption 0.778 <4 drinks/day	> 30	1.16 (1.04, 1.30)	0.010	
No 1.33 (1.05, 1.69) 0.017 Alcohol consumption 0.778 <4 drinks/day	Smoking status			0.400
Alcohol consumption 0.778 <4 drinks/day	Yes	1.20 (1.10, 1.30)	< 0.001	
$<4 \text{ drinks/day}$ $1.21 (1.10, 1.33)$ <0.001 $\geq 4 \text{ drinks/day}$ $1.24 (1.07, 1.45)$ 0.006 Diabetes 0.313 Yes $1.33 (1.12, 1.57)$ 0.001 No $1.20 (1.09, 1.32)$ <0.001 Hypertension 0.364 Yes $1.26 (1.13, 1.41)$ <0.001 No $1.17 (1.05, 1.31)$ 0.006 Sedentary time, h 0.838 $<3h$ $1.25 (1.03, 1.52)$ 0.013	No	1.33 (1.05, 1.69)	0.017	
≥4 drinks/day 1.24 (1.07, 1.45) 0.006 Diabetes 0.313 Yes 1.33 (1.12, 1.57) 0.001 No 1.20 (1.09, 1.32) <0.001	Alcohol consumption			0.778
Diabetes 0.313 Yes 1.33 (1.12, 1.57) 0.001 No 1.20 (1.09, 1.32) <0.001	<4 drinks/day	1.21 (1.10, 1.33)	< 0.001	
Yes 1.33 (1.12, 1.57) 0.001 No 1.20 (1.09, 1.32) <0.001	\geq 4 drinks/day	1.24 (1.07, 1.45)	0.006	
No 1.20 (1.09, 1.32) <0.001 Hypertension 0.364 Yes 1.26 (1.13, 1.41) <0.001	Diabetes			0.313
Hypertension 0.364 Yes 1.26 (1.13, 1.41) <0.001	Yes	1.33 (1.12, 1.57)	0.001	
Yes 1.26 (1.13, 1.41) <0.001 No 1.17 (1.05, 1.31) 0.006 Sedentary time, h 0.838 <3 h	No	1.20 (1.09, 1.32)	< 0.001	
No 1.17 (1.05, 1.31) 0.006 Sedentary time, h 0.838 <3 h	Hypertension			0.364
Sedentary time, h 0.838 <3 h	Yes	1.26 (1.13, 1.41)	< 0.001	
<3 h 1.25 (1.03, 1.52) 0.026 3-6 h 1.18 (1.04, 1.35) 0.013	No	1.17 (1.05, 1.31)	0.006	
3–6 h 1.18 (1.04, 1.35) 0.013	Sedentary time, h			0.838
	<3 h	1.25 (1.03, 1.52)	0.026	
>6 h 1.24 (1.11, 1.40) <0.001	3-6 h	1.18 (1.04, 1.35)	0.013	
	>6 h	1.24 (1.11, 1.40)	< 0.001	

TABLE 3 Subgroup analysis of the correlation between $\mathsf{Log}_{\mathsf{2}}\mathsf{HbEtO}$ levels and CB.

PIRs, poverty-to-income ratios; Log₂HbEtO, Natural Log₂-transformed hemoglobin adducts of ethylene oxide; BMI, body mass index; CB, chronic bronchitis.

be deprioritized due to the assumption that their direct health risks are lower. Third, NHANES typically targets specific exposure tests at individuals with known risk factors, resulting in higher rates of missing data among those considered lower risk, such as younger individuals.

This study utilized data from a U.S. population sample to examine the association between ethylene oxide (EtO) exposure and CB, offering valuable insights into the respiratory impact of this widely used industrial compound. To enhance the reliability of our findings, we conducted subgroup analyses and carefully adjusted for key confounders. Nonetheless, several limitations warrant consideration. First, the reliance on self-reported CB data may introduce recall bias and potential misclassification. Additionally, the cross-sectional study design limits causal interpretation, as it does not allow for establishing the temporal sequence between EtO exposure and CB onset. Furthermore, the NHANES database lacks specific information on respiratory infections and occupational history, limiting our ability to assess infection-related risks or distinguish between occupational and environmental EtO exposure sources. Although adjustments were made for smoking status, residual confounding may still exist due to unmeasured factors such as smoking intensity, duration, and passive exposure. Also, since EtO levels may vary over time, a single measurement may not adequately reflect cumulative exposure. Future research, particularly longitudinal studies, is essential to deepen our understanding of EtO exposure's impact on CB risk and to address these limitations.

5 Conclusion

The findings of this study indicate a significant association between EtO exposure and CB, with a fitted smoothing curve revealing a U-shaped association pattern. However, the crosssectional design limits causal inference, and unmeasured confounders, such as exposure to other environmental pollutants, may have influenced the results. Additionally, HbEtO, while used as a marker for EtO exposure, may not fully capture long-term exposure, potentially leading to misclassification. Although the NHANES sample is not globally representative, this study underscores the importance of monitoring and controlling EtO exposure to reduce its potential adverse effects on respiratory health. Future research should investigate the specific mechanisms through which EtO exposure impacts bronchial health and seek to validate and expand upon these findings.

Data availability statement

Publicly available datasets were analyzed in this study. This data can be found here: https://wwwn.cdc.gov/nchs/nhanes.

Ethics statement

The studies involving humans were approved by National Health Council Research Ethics Assessment Board. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants' legal guardians/next of kin.

Author contributions

YL: Conceptualization, Data curation, Formal analysis, Methodology, Software, Supervision, Visualization, Writing – original draft, Writing – review & editing. HW: Methodology, Software, Visualization, Writing – original draft. XB: Data curation, Software, Visualization, Writing – review & editing. GZ: Formal analysis, Investigation, Resources, Supervision, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Acknowledgments

The authors acknowledge the National Health and Nutrition Examination Survey (NHANES) participants for their invaluable contributions to this research.

References

1. Sunyer J, Jarvis D, Gotschi T, Garcia-Esteban R, Jacquemin B, Aguilera I, et al. Chronic bronchitis and urban air pollution in an international study. *Occup Environ Med.* (2006) 63:836–43. doi: 10.1136/oem.2006.027995

2. Lynch DW, Lewis TR, Moorman WJ, Burg JR, Groth DH, Khan A, et al. Carcinogenic and toxicologic effects of inhaled ethylene oxide and propylene oxide in F344 rats. *Toxicol Appl Pharmacol.* (1984) 76:69–84. doi: 10.1016/0041-008x(84)90030-9

3. Yu S, Zhu Q, Yu M, Zhou C, Meng R, Bai G, et al. The association between longterm exposure to ambient formaldehyde and respiratory mortality risk: a national study in China. *Ecotoxicol Environ Saf.* (2024) 283:116860. doi: 10.1016/j.ecoenv.2024.116860

4. Tian F, Zhong X, Ye Y, Liu X, He G, Wu C, et al. Mutual associations of exposure to ambient air pollutants in the first 1000 days of life with asthma/wheezing in children: prospective cohort study in Guangzhou, China. *JMIR Public Health Surveill*. (2024) 10:e52456. doi: 10.2196/52456

5. Filser JG, Denk B, Törnqvist M, Kessler W, Ehrenberg L. Pharmacokinetics of ethylene in man; body burden with ethylene oxide and hydroxyethylation of hemoglobin due to endogenous and environmental ethylene. *Arch Toxicol.* (1992) 66:157–63. doi: 10.1007/BF01974008

 Schettgen T, Broding HC, Angerer J, Drexler H. Hemoglobin adducts of ethylene oxide, propylene oxide, acrylonitrile and acrylamidebiomarkers in occupational and environmental medicine. *Toxicol Lett.* (2002) 134:65-70. doi: 10.1016/s0378-4274(02)00164-9

7. Li F, Segal A, Solomon JJ. *In vitro* reaction of ethylene oxide with DNA and characterization of DNA adducts. *Chem Biol Interact.* (1992) 83:35-54. doi: 10.1016/0009-2797(92)90090-8

8. Swenberg JA, Ham A, Koc H, Morinello E, Ranasinghe A, Tretyakova N, et al. adducts: effects of low exposure to ethylene oxide, vinyl chloride and butadiene. *Mutat Res.* (2000) 464:77–86. doi: 10.1016/s1383-5718(99)00168-0

9. Ghosh M, Godderis L. Genotoxicity of ethylene oxide: a review of micronucleus assay results in human population. *Mutat Res Rev Mutat Res.* (2016) 770:84–91. doi: 10.1016/j.mrrev.2016.05.002

10. Brockmann WG, Kostoryz EL, Eick JD. Correlation of apoptotic potential of simple oxiranes with cytotoxicity. *Toxicol Vitro Int J Publ Assoc BIBRA*. (2006) 20:729–35. doi: 10.1016/j.tiv.2005.10.009

11. Li S, Wang J, Lei D, Peng D, Zong K, Li K, et al. Associations between ethylene oxide exposure and liver function in the US adult population. *Toxics.* (2024) 12:551. doi: 10.3390/toxics12080551

12. Guo J, Garshick E, Si F, Tang Z, Lian X, Wang Y, et al. Environmental toxicant exposure and depressive symptoms. *JAMA Netw Open.* (2024) 7:e2420259. doi: 10.1001/jamanetworkopen.2024.20259

13. Zhou C, Wang S, Ju L, Zhang R, Yang Y, Liu Y. Positive association between blood ethylene oxide levels and metabolic syndrome: NHANES

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2024. 1424555/full#supplementary-material

2013-2020. Front Endocrinol. (2024) 15:1365658. doi: 10.3389/fendo.2024.13 65658

14. Garvey M. Medical device-associated healthcare infections: sterilization and the potential of novel biological approaches to ensure patient safety. *Int J Mol Sci.* (2023) 25:201. doi: 10.3390/ijms25010201

15. Rahman HH, Niemann D, Munson-McGee SH. Urinary metals, arsenic, and polycyclic aromatic hydrocarbon exposure and risk of chronic bronchitis in the US adult population. *Environ Sci Pollut Res Int.* (2022) 29:73480–91. doi: 10.1007/s11356-022-20982-9

16. Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. *Lancet Respir Med.* (2022) 10:447–58. doi: 10.1016/S2213-2600(21)00511-7

17. Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* (2013) 187:228–37. doi: 10.1164/rccm.201210-1843CI

18. Lin Z, Xiong J, Yang J, Huang Y, Li J, Zhao G, et al. comprehensive analysis of the health effects associated with smoking in the largest population using UK Biobank genotypic and phenotypic data. *Heliyon.* (2024) 10:e35649. doi: 10.1016/j.heliyon.2024.e35649

19. Zavala-Arciniega L, Cook S, Hirschtick JL, Xie Y, Mukerjee R, Arenberg D, et al. Longitudinal associations between exclusive, dual and polytobacco use and respiratory illness among youth. *BMC Public Health.* (2024) 24:2159. doi: 10.1186/s12889-024-19582-8

20. Cerveri I, Accordini S, Verlato G, Corsico A, Zoia MC, Casali L, et al. European Community Respiratory Health Survey (ECRHS) Study Group. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. *Eur Respir J.* (2001) 18:85–92. doi: 10.1183/09031936.01.00087101

21. Estrin WJ, Bowler RM, Lash A, Becker CE. Neurotoxicological evaluation of hospital sterilizer workers exposed to ethylene oxide. *J Toxicol Clin Toxicol.* (1990) 28:1–20. doi: 10.3109/15563659008993472

22. Brashear A, Unverzagt FW, Farber MO, Bonnin JM, Garcia JG, Grober E. Ethylene oxide neurotoxicity: a cluster of 12 nurses with peripheral and central nervous system toxicity. *Neurology*. (1996) 46:992–8. doi: 10.1212/wnl.46.4.992

23. Xie R, Liu L, Liu C, Xie S, Huang X, Zhang Y. Associations of ethylene oxide exposure and "Life's Essential 8". *Environ Sci Pollut Res Int.* (2023) 30:121150–60. doi: 10.1007/s11356-023-30741-z

24. Qin Z, Zhao J, Geng J, Chang K, Liao R, Su B. Higher triglyceride–glucose index is associated with increased likelihood of kidney stones. *Front Endocrinol.* (2021) 12:774567. doi: 10.3389/fendo.2021.774567

25. Mendy A, Salo PM, Cohn RD, Wilkerson J, Zeldin DC, Thorne PS. House dust endotoxin association with chronic bronchitis and emphysema. *Environ Health Perspect.* (2018) 126:037007. doi: 10.1289/EHP2452

Li et al.

26. Wang H, Chen X, Lin F, Zheng J, Chen K, Wang X, et al. Association between ethylene oxide levels and depressive symptoms: a cross-sectional study based on NHANES 2013-2018 database. *J Affect Disord.* (2024) 348:135-42. doi: 10.1016/j.jad.2023.12.050

27. Huang Q, Li S, Wan J, Nan W, He B. Association between ethylene oxide exposure and prevalence of COPD: evidence from NHANES 2013-2016. *Sci Total Environ.* (2023) 885:163871. doi: 10.1016/j.scitotenv.2023.163871

28. Li Z, Shi P, Chen Z, Zhang W, Lin S, Zheng T, et al. The association between ethylene oxide exposure and asthma risk: a population-based study. *Environ Sci Pollut Res Int.* (2023) 30:24154–67. doi: 10.1007/s11356-022-23782-3

29. Han L, Wang Q. Association between hemoglobin adducts of ethylene oxide levels and the risk of short sleep duration in the general population: an analysis based on the National Health and Nutrition Examination Survey. *Environ Sci Pollut Res Int.* (2023) 30:76761–8. doi: 10.1007/s11356-023-27734-3

30. Zhu X, Kong X, Chen M, Shi S, Cheang I, Zhu Q, et al. Blood ethylene oxide, systemic inflammation, and serum lipid profiles: Results from NHANES 2013-2016. *Chemosphere*. (2022) 299:134336. doi: 10.1016/j.chemosphere.2022.134336

31. Wu N, Cao W, Wang Y, Liu X. Association between blood ethylene oxide levels and the prevalence of hypertension. *Environ Sci Pollut Res Int.* (2022) 29:76937– 43. doi: 10.1007/s11356-022-21130-z

32. Zhao Y, Zhao J, Xie R, Zhang Y, Xu Y, Mao J, Yan C, Sun Y. Association between family income to poverty ratio and HPV infection status among U.S. women aged 20 years and older: a study from NHANES 2003-2016. *Front Oncol.* (2023) 13:1263356. doi: 10.3389/fonc.2023.1263356

33. Zhang Y, Liu M, Xie R. Associations between cadmium exposure and wholebody aging: mediation analysis in the NHANES. *BMC Public Health.* (2023) 23:1675. doi: 10.1186/s12889-023-16643-2

34. Landrigan PJ, Meinhardt TJ, Gordon J, Lipscomb JA, Burg JR, Mazzuckelli LF, et al. Ethylene oxide: an overview of toxicologic and epidemiologic research. *Am J Ind Med.* (1984) 6:103–15. doi: 10.1002/ajim.4700060205

35. Vincent MJ, Kozal JS, Thompson WJ, Maier A, Dotson GS, Best EA, et al. Ethylene oxide: cancer evidence integration and dose-response implications. *Dose-Response Publ Int Hormesis Soc.* (2019) 17:1559325819888317. doi: 10.1177/1559325819888317

36. Jinot J, Fritz JM, Vulimiri SV, Keshava N. Carcinogenicity of ethylene oxide: key findings and scientific issues. *Toxicol Mech Methods*. (2018) 28:386–96. doi: 10.1080/15376516.2017.1414343

37. Kolman A, Näslund M, Calleman CJ. Genotoxic effects of ethylene oxide and their relevance to human cancer. *Carcinogenesis.* (1986) 7:1245–50. doi: 10.1093/carcin/7.8.1245

38. Rasool M, Malik A, Abdul Basit Ashraf M, Mubbin R, Ayyaz U, Waquar S, et al. Phytochemical analysis and protective effects of *Vaccinium macrocarpon* (cranberry) in rats (*Rattus norvegicus*) following ethylene oxide-induced oxidative insult. *Bioengineered*. (2021) 12:4593–604. doi: 10.1080/21655979.2021.1955528

39. Cheang I, Zhu X, Zhu Q, Li M, Liao S, Zuo Z, et al. Inverse association between blood ethylene oxide levels and obesity in the general population: NHANES 2013-2016. *Front Endocrinol.* (2022) 13:926971. doi: 10.3389/fendo.2022.926971

40. Guo J, Wan Z, Cui G, Pan A, Liu G. Association of exposure to ethylene oxide with risk of diabetes mellitus: results from NHANES 2013-2016. *Environ Sci Pollut Res Int*. (2021) 28:68551–9. doi: 10.1007/s11356-021-15444-7

41. Klonne DR, Dodd DE, Losco PE, Troup CM, Tyler TR. Pulmonary fibrosis produced in F-344 rats by subchronic inhalation of aerosols of a 4000 molecular weight ethylene oxide/propylene oxide polymer. *Fundam Appl Toxicol Off J Soc Toxicol.* (1988) 10:682–90. doi: 10.1016/0272-0590(88)90195-9

42. National Toxicology Program. NTP toxicology and carcinogenesis studies of ethylene oxide (CAS No. 75-21-8) in B6C3F1 mice (inhalation studies). *Natl Toxicol Program Tech Rep Ser.* (1987) 326:1–114.

43. Adedara IA, Farombi EO. Induction of oxidative damage in the testes and spermatozoa and hematotoxicity in rats exposed to multiple doses of ethylene glycol monoethyl ether. *Hum Exp Toxicol.* (2010) 29:801–12. doi: 10.1177/0960327109360115

44. Jain RB. Associations between observed concentrations of ethylene oxide in whole blood and smoking, exposure to environmental tobacco smoke, and cancers including breast cancer: data for US children, adolescents, and adults. *Environ Sci Pollut Res Int.* (2020) 27:20912–9. doi: 10.1007/s11356-020-08564-z

45. Lynch HN, Kozal JS, Russell AJ, Thompson WJ, Divis HR, Freid RD, et al. Systematic review of the scientific evidence on ethylene oxide as a human carcinogen. *Chem Biol Interact.* (2022) 364:110031. doi: 10.1016/j.cbi.2022. 110031